Nice Result. If you look properly at the Quarter Report, the profit on 2018 Q3 is lower than 2017 Q3 is because of the "Profit from discontinued operations, net of tax" on 2017 Q3. Also, the revenue and profit of current quarter is actually growing from the previous quarter. From the report, it can be seen that the management is reducing the expenses and making more revenue. Apart from that, dont forget of the theme of this stock, which is the capability to win job to supply caustic soda to Rapid. Buy CALL
In Fact, if you remove the "Profit from discontinued operations, net of tax" on 2017 Q3. The y-o-y profit growth rate is actually more than 1000%. Cheer
Management objectives for this year are to improvement performance of existing businesses (chemical and polymer) and improved the balance sheet of the company via disposal of non core assets. As of 3Q, both of these has actually improved.
I was expecting a higher profit though. Notice that the main reason for the lower profit in 3q was the high tax rate. Rm5mil tax for PBT of rm10mil. Anyone knows why? Another issue is the caustic price which has gone down by a lot.
Still with Rapid next year, outlook remains bright on condition that the caustic price will recover back to usd500/ tonne level.
Yes, rapid is the next positive catalyst for the company given that CCM has already a chemical plant located in Pasir Gudang compared to the other big caustic soda player, Malay Sino Industries whose plants are located in Perak and Terengganu. Rapid will need around 100MT of caustic soda for its refinery once it starts operations. This is why management are planning to spend at least RM68mil to increase the Pasir Gudang plant capacity by another 50% which is expected to be completed by mid of next year.
However, you need to take note that the financial performance of the company is still highly dependent on the price of South East Asia caustic soda. Hong Leong analyst are projecting a profit of around RM40mil for the company in FY19. But this projection is still based on a caustic price of USD500/tonne. As of early Dec, South East Asia caustic price has fallen to only USD346/tonne vs more than USD600 a year ago. Until the price rebound back to USD500, it might be a while before CCM will be able to deliver a profit of more than RM40mil to its investors. The caustic price is tracked on a weekly basis which you can check via the Bloomberg Platform.
If you are looking to diversify your portfolio outside of CCM (due to the volatility of the caustic soda price), I would recommend you to look at MBMR.
MBMR is a direct proxy to Perodua via its 22.6% interest in the company. Valuation is cheap at only 5.5x PE (based on target FY18 PATAMI of RM145mil. 9m PATAMI is already RM106mil). PB is low at only 0.5x BV. 4Q18 results is expected to be higher than 3Q18 and last year's 4Q17.
For FY19 growth will be driven by the still high demand of new Myvi and the launch of the new SUV in 1Q19 and also the new Alza in 2H19.
Please go through the analyst reports (https://klse.i3investor.com/servlets/stk/pt/5983.jsp) and do your own analysis before making any decisions. Most analysts have a TP of above RM3 for the company with Hong Leong being the lowest at RM3.13 and Maybank the highest at RM4.18.
I think the financial performance of the company will be affected by the falling caustic soda price. It will take time for the price to rebound to previous high level. Hence, CCM will probably deliver a weaker qoq results for Q4. Also, if you look at 1Q2018, the results was good due to high caustic soda price in 1Q2018. Moving to 1Q2019, there will be a high base comparison.It will be challenging for the company to surpass the 1Q2018 if caustic soda price is not rebounding. Please be aware of this.
Today's slump of glove counter's share price is most probably because of the concerns on glove oversupply. This make me worry on whether CCM's polymer business will be affected moving forward.
According to research report, CCM has direct exposure to glove sector due to its polymer is used in glove manufacturing process. To note, polymer segment account for c.23% of group’s revenues and c.30% of PBT.
DHM explained that Pharmaniaga is only responsible for the logistics of supplying drugs to government health facilities, rather than the supply itself.
“The big problem is price control, not Pharmaniaga,” says MyCC
Social activist Lim Mah Hui, one of the conductors of the MyCC study, said Pharmaniaga did not have a monopoly over supply but a virtual monopoly over logistics.
The public need to understand that Pharmaniaga's role as a concessionaire and not immediately liken it to a monopoly. Shared some thoughts in this article (https://klse.i3investor.com/blogs/MYpharmaceuticalnews/228733.jsp). Though it could use a bit more context but hope this can get the conversation going.
This book is the result of the author's many years of experience and observation throughout his 26 years in the stockbroking industry. It was written for general public to learn to invest based on facts and not on fantasies or hearsay....
wai011
7 posts
Posted by wai011 > 2018-09-01 22:48 | Report Abuse
@cricketlast, did you observed Q2 FY18 recorded higher non-controlling interest? Why the amount so high in that quarter?